Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From UCB S.A.
The yet-to-be-named medtech company will focus on orthopedic implants and bracing and recovery devices.
Plus deals involving WuXi AppTec/OXGENE, Oscotec/Beatica, ReViral/LianBio, Wugen/HCW Biologics, Starton/Haisco, Shanghai Junshi/AstraZeneca, HitGen/Uppthera, Bridge/LegoChem, Macrogen/Lifex, BeiGene/Boston Immune
Hyloris has secured licensing deals with Aguettant for its Maxigesic IV combination of paracetamol and ibuprofen in a further eight European markets through partner AFT Pharmaceuticals.
Belgium’s UCB Pharma is expecting progress with new candidates for myasthenia gravis, psoriasis and osteoporosis this year.
- Research, Analytical Equipment & Supplies
Drug Discovery Tools
- Drug Discovery Tools
- Other Names / Subsidiaries
- Celltech Pharmaceuticals, Inc.
- Element Genomics
- Engage Therapeutics, Inc., Ra Pharmaceuticals, Inc.
- Schwarz Pharma
- Upstate Pharma, LLC